Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor.
Florian BöschAnnelore Altendorf-HofmannSven JacobChristoph Josef AuernhammerChristine SpitzwegStefan BoeckGabriele Schubert-FritschleJens WernerThomas KirchnerMartin K AngeleThomas KnöselPublished in: Journal of clinical medicine (2020)
VEGFR 1-3 show a distinct expression pattern in different subgroups of neuroendocrine neoplasias indicating a conceivable target. Moreover, there was a substantial association between VEGFRs and immune checkpoint markers. Taken together, anti-VEGFR therapy represents a promising therapeutic approach in GEP-NEN patients and should be addressed in future studies.